Share on Facebook
Share on Twitter
Share on LinkedIn
Share on Reddit
Share by Email
Print
美女免费一级视频在线观看
Deals:
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion.
Bristol Myers Squibb will pay $1.5 billion upfront to partner with BioNTech on an experimental cancer drug.
Astellas Pharma announced a deal that could exceed $1.4 billion with Evopoint Biosciences.
Eli Lilly has tapped Camurus in a deal worth up to $870 million for its drug delivery technology to develop four long-acting incretin candidates.
Atai Life Sciences is merging with Beckley Psytech in a $370 million deal.
Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor – the deal could total up to $2 billion.
Function Health is acquiring Ezra.
Alvotech and Dr. Reddy’s entered into a Collaboration to Co-Develop Biosimilar Candidate to Merck’s Keytruda (pembrolizumab).
Pyx Health bought FarmboxRx.
WellTheory launched its first-ever health plan partnership with Sentara Healthcare.
FDA:
The FDA launched an agencywide generative AI tool aimed at helping scientific reviewers, investigators and others streamline their work.
The agency granted orphan drug designation to Sanofi’s rilzabrutinib.
The FDA approved Moderna‘s next-generation COVID-19 vaccine for adults 65 and older and those 12 to 64 years old who are at risk of severe infection.
The agency is elevating an earlier tomato recall to its highest risk level over concerns of potential salmonella contamination.
Funding rounds:
Omada Health targeted a valuation of over $1 billion in its IPO.
Elon Musk’s Neuralink raised $650 million in its latest late stage funding round.
Amplify Partners raised $200 million.
Allay Therapeutics raised a $57.5 million Series D financing round.
Antheia announced $56 million in Series C funding in a round led by GHIC and EDBI.
CinDome Pharma collected an additional $40 million from existing investors.
Layoffs:
Rapt Therapeutics conducted its second round of layoffs in just under a year.
Protein degradation company Plexium laid off staff as part of a realignment.
Industry news:
Amgen’s drug Imdelltra cut small cancer lung cell death risk by 40%.
Regeneron said its weight loss drug helped patients on Novo Nordisk’s Wegovy retain muscle.
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump administration’s pullback in aid spending.
UniQure’s investigational gene therapy AMT-260 sharply reduced seizure frequency in the first participant of its Phase 1/2a trial for drug-resistant mesial temporal lobe epilepsy.
Illumina debuted PromoterAI.
The Centers for Disease Control and Prevention published a report showing that nasal irrigation with tap water is a risk factor for a rare and potentially fatal brain infection.
Summit Therapeutics and Akeso’s PD-1xVEGF bispecific hit on progression-free survival in a keenly-awaited Phase 3 lung cancer trial, but missed the other primary endpoint.
Sandoz launched the first and only interchangeable denosumab biosimilars in the U.S.
Johnson & Johnson reported data from a Phase 1 trial of prostate cancer drug.
J&J’s Akeega tablet showed delay in cancer progression in a Phase 3 trial.
5WPR launched the Aging Solutions Group.
Austin, Texas-based biotechnology company Molecular Templates filed for Chapter 11 bankruptcy.
Vantive announced its plan to invest more than $1 billion over the next five years in expanding research and development as well as production capacity.
Gilead’s Trodelvy and Merck’s Keytruda to become new standard of care for frontline TNBC, per recently published studies.
AstraZeneca’s Imfinzi regimen shows early promise in a hard-to-treat cancer.
Novartis’ cancer treatment Pluvicto showed positive results in a trial.
Novartis also reported new data from the Phase 2 trial of Kisqali in breast cancer.
Sanofi published data on investigational Sarclisa SC, delivered by an on-body device, that measured up to its IV formulation.
Sanofi and Regeneron’s respiratory drug delivered mixed results in key trials.
The Trump administration announced it is rescinding Biden-era guidance that uses a federal law to require hospitals to stabilize patients in need of emergency care – including by providing an abortion.
Pfizer’s Braftovi doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial data.
Merck’s antibody drug conjugate asset shows antitumor activity in phase 2
An experimental medicine from Vera Therapeutics significantly reduced levels of toxic protein in the urine of patients with an autoimmune kidney disease, according to Phase 3 study results.
Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.
Lilly announced new Phase 1 data for LY4170156 at ASCO
The Federal Bureau of Investigation requested tips from the public on hospitals, clinics or practitioners performing gender-affirming surgeries to youth.
Sensodent, Indoco Remedies‘ specialized oral care brand, appointed Initiative, a 2024 MM+M Agency 100 honoree, as its media agency of record.
Quantum BioPharma clarified it has not changed its name.
America’s Blood Centers and the American College of Surgeons’ Stop the Bleed program, announced a new national collaboration during National Trauma Awareness Month and National Stop the Bleed Month.
A U.S. Patent and Trademark Office panel agreed to reconsider a patent granted to Halozyme Therapeutics that could affect Merck‘s plans to broaden the use of Keytruda.
Vigil Neuroscience said its candidate to treat a rare brain disease failed a Phase 2 trial.
Casma Therapeutics is unveiling its first preclinical data suggesting that a novel drug can enhance the ability of brain cells to clear out molecular garbage.
